The US Food and Drug Administration announced on May 16 it has granted digital health care provider Notal Vision’s de novo marketing authorization for its patient self-operated Scanly Home optical coherence tomography device for monitoring age-related macular degeneration.
Designated by the FDA as a breakthrough device for patients suffering from neovascular, age-related macular degeneration or nvAMD, the leading...






